Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selected Start-Ups (02/01)

Executive Summary

In Vivo summarizes the technology of several recently founded companies: Clinsights Inc. provides web-based post-market clinical and sales support for medical device and pharmaceutical companies and physicians. CombinatoRx Inc. hopes to develop the next generation of pharmaceuticals using new theories of how therapeutics should interact with the complex components of cells. Gyros AB has developed technology for miniaturizing and integrating routine and non-routine laboratory processes on disposable CDs. Innovative Drug Delivery Systems Inc. will develop and commercialize unique nasally administered compounds to treat acute and chronic pain and their associated symptoms. PhytaGenics will use its proprietary rapid, high-volume transgenic production technology to create recombinant biopharmaceutical proteins in plants. StemCo Biomedical Inc.'s stem cell platform is capable of identifying and isolating healthy stem cells from contaminating cells, and can be used in repopulating blood systems or regenerating organs and tissue.

You may also be interested in...



Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.

Related Companies

UsernamePublicRestriction

Register

IV001604

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel